Darwin Global Management Ltd. Invests $3.08 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Darwin Global Management Ltd. bought a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 163,681 shares of the company's stock, valued at approximately $3,084,000. Nurix Therapeutics makes up approximately 0.3% of Darwin Global Management Ltd.'s investment portfolio, making the stock its 6th largest position. Darwin Global Management Ltd. owned about 0.22% of Nurix Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Northern Trust Corp raised its stake in Nurix Therapeutics by 16.4% in the fourth quarter. Northern Trust Corp now owns 659,788 shares of the company's stock valued at $12,430,000 after buying an additional 92,933 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Nurix Therapeutics by 2.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock valued at $585,000 after acquiring an additional 642 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Nurix Therapeutics during the fourth quarter worth about $87,000. Lord Abbett & CO. LLC grew its holdings in Nurix Therapeutics by 24.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 437,772 shares of the company's stock valued at $8,248,000 after buying an additional 87,132 shares in the last quarter. Finally, Voya Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 171.8% during the 4th quarter. Voya Investment Management LLC now owns 55,079 shares of the company's stock worth $1,038,000 after buying an additional 34,811 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on NRIX shares. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Royal Bank of Canada increased their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lowered their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Leerink Partners began coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They set a "market perform" rating and a $16.00 target price on the stock. Finally, Morgan Stanley raised their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research note on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.44.

Insider Buying and Selling

In related news, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider now directly owns 61,516 shares of the company's stock, valued at $707,434. This represents a 5.20 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $382,092.92. This represents a 15.53 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Stock Up 1.0 %

Shares of NRIX traded up $0.11 on Friday, reaching $11.27. The stock had a trading volume of 599,966 shares, compared to its average volume of 888,254. The firm has a 50-day moving average of $12.03 and a 200 day moving average of $17.93. The firm has a market capitalization of $859.18 million, a PE ratio of -3.90 and a beta of 2.23. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The business had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. During the same quarter last year, the firm earned ($0.76) earnings per share. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.